Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,173.91
(
0.12%
)
US TECH 100
26,615.60
(
0.23%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
102.49
(
0.37%
)
Bitcoin
77,260.79
(
-0.14%
)
News Focus
News Focus
Post# of 257453
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech_researcher post# 202168

Wednesday, 06/22/2016 10:45:22 AM

Wednesday, June 22, 2016 10:45:22 AM

Post# of 257453
OCRX—The only new info is that ~180 patients (of the required 230) have been enrolled in the STOP-HE trial:

https://www.sec.gov/Archives/edgar/data/1274644/000127464416000121/ocera-form8xk7011.htm

The 180 number is a little low but not far off from the company's prior guidance, so this is not a big deal, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today